INTRODUCTION

Locoregional recurrence of differentiated thyroid cancer (DTC) occurs in 20% of thyroid cancer patients.² For this reason, multidisciplinary tumor boards have been created to manage DTC in a multimodal manner. This has enabled different therapeutic strategies based on local treatments such as surgery, enolization, embolization, or radiotherapy to be used primarily in early-stage DTC aiming for cure of the disease.²

The objective of this paper is to review the available literature on the use of various locoregional techniques for management of advanced radioiodine-refractory DTC (RR-DTC) in the absence of clinical trials that combine these techniques with multikinase inhibitors (MKIs).

HISTORICAL PERSPECTIVE

Several years ago, new MKIs were introduced for the treatment of RR-DTC and have become the current standard in this clinical scenario. Because lenvatinib therapy is active in patients with locally advanced thyroid cancers not operable due to high risk of perioperative complications (including in those naïve to radioactive iodine), some patients may benefit from modifications in the treatment sequence.³,⁴ The most likely situation involves a need for surgical intervention while receiving systemic therapy. Specifically, ‘oligoprogression’ may happen in some tumors with insidious growth leading to metastases progressing at different rates.³ In this context, use of locoregional techniques concomitant with MKI treatment could be the best option to manage RR-DTC presenting...
with this heterogeneous behavior. However, there are scarce published data for this approach in thyroid cancer, primarily because of the relatively short time since the approval of MKIs in this scenario and the heterogeneity of the clinical presentations. The objective of this review is to clarify the published data to facilitate the management of patients with RR-DTC.

3 | CURRENT SITUATION AND TREATMENT RECOMMENDATIONS

The different approaches to treatment of RR-DTC that can be considered are described below.

3.1 | Surgery

Use of surgery in disseminated disease is unusual, although it may be considered in circumstances in which the systemic disease is controlled or has achieved a response and, as mentioned before, there is oligoprogression. Having said this, given that the functional integrity of the neck is difficult to preserve with multiple surgeries, it is recommended to manage MKI-unresponsive disease mainly in anatomic locations other than the neck. Thus, surgery may be considered for patients with single distant metastases, including patients with a single bone metastasis, brain metastases, or limited pulmonary metastases. The 5-year survival for 31 patients with papillary cancer after thoracic metastectomy was 64%, and radical surgical extirpation of isolated bone metastases is associated with improved survival.1

Surgery has been proved helpful in the management of DTC in conjunction with lenvatinib, with excellent results.6–9 However, it is worth mentioning that impaired wound healing has been reported in patients receiving lenvatinib despite no formal research on this phenomenon having been done to date.10 Therefore, temporary interruption of lenvatinib treatment should be considered for patients undergoing major surgical procedures. Based on its half-life of 28 hours measured in healthy volunteers, recommendations made in a phase III trial of patients with advanced renal cell carcinoma (aRCC) likely to receive surgery during the study, can be extrapolated to the thyroid cancer population.11 In addition, a real-life study has recently been published from a major Japanese hospital, where Toda et al show that their experience with invasive procedures in 14 patients treated with lenvatinib is consistent with the following recommendations:12:

• For minor procedures: stop lenvatinib at least 2 days before the surgery and restart it at least 2 days after, once there is evidence of adequate healing and no risk of bleeding.

Caution is advised as these recommendations were made for patients with aRCC receiving lenvatinib.11 However, they are likely to be applicable to patients with normal renal and hepatic function, thus with expected normal drug clearance. Despite the scarcity of robust clinical data, surgery with concomitant lenvatinib is a possible option to manage RR-DTC patients.

A promising and possible strategy reported by several clinical cases13 and that is being tested in several clinical trials (Table 1) is the use of MKIs for neoadjuvant treatment of thyroid cancer. However, more robust data are needed for standardization in clinical practice. In that case, it will be necessary to determine which are the appropriate candidates and which tumor factors benefit most from said strategy.

3.2 | Enolization

Enolization consists of percutaneous ethanol injection to limited cervical lymph node metastases. Long-term local control can be achieved, and the technique is not associated with major complications. However, treatment is sometimes necessary.14 As with surgery, there are no data available for combining this technique with MKI.

3.3 | Radiofrequency ablation

Radiofrequency ablation (RFA) has been used primarily for liver tumors as an alternative to a surgical procedure. RFA of cervical, osseous, and pulmonary metastases is an alternative for patients who are poor surgical candidates and whose metastases do not concentrate radioiodine, but expertise in this treatment modality is not widely available.15 Furthermore, RFA can be used before surgery to improve surgical results and reduce morbidity and mortality.16 In the same way as other techniques, there are no data supported by clinical trials that generate sufficient scientific evidence. However, Porcelli et al, when reviewing other pathologies, conclude that it may be feasible to use these ablative techniques for the local control of oligoprogressive thyroid cancer.17

3.4 | Embolization

Embolization has generally been used as adjuvant therapy to reduce surgical bleeding in patients with large or very vascular
### Table 1: Clinical trials with tyrosine kinase inhibitors and local interventions in differentiated thyroid cancer

| Clinical trial number | Title                                                                 | Phase | N  | Type of Cancer                          | Locoregional Intervention                                      |
|-----------------------|----------------------------------------------------------------------|-------|----|----------------------------------------|----------------------------------------------------------------|
| NCT03975231           | Dabrafenib, Trametinib, and IMRT in Treating Patients With BRAF Mutated Anaplastic Thyroid Cancer | I     | 20 | Anaplastic Thyroid Cancer              | Radiation: Intensity-Modulated Radiation Therapy (IMRT)         |
| NCT04321954           | Lenvatinib in Locally Advanced Invasive Thyroid Cancer                | II    | 30 | Any thyroid cancer (excluded medullary or anaplastic thyroid cancer) | Procedure: Therapeutic Conventional Surgery                     |
| NCT04759911           | Selpercatinib Before Surgery for the Treatment of RET-Altered Thyroid Cancer | II    | 30 | Medullary Thyroid Cancer               | Procedure: Therapeutic Conventional Surgery                     |
| NCT04739566           | Dabrafenib and Trametinib Combination as a Neoadjuvant Strategy in BRAF-positive Anaplastic Thyroid Cancer | II    | 18 | Anaplastic Thyroid Cancer              | Procedure: Conventional Surgery                                 |
| NCT04675710           | Pembrolizumab, Dabrafenib, and Trametinib Before Surgery for the Treatment of BRAF- Mutated Anaplastic Thyroid Cancer | II    | 30 | Anaplastic Thyroid Cancer              | Procedure: Conventional Surgery                                 |
|                       |                                                                       |       |    |                                        | • Radiation: Intensity-Modulated Radiation Therapy              |
| NCT04693377           | Cryoablation Combined With Stereotactic Body Radiation Therapy for the Treatment of Painful Bone Metastases, the CROME Trial | NA   | 40 | Any cancer with low alpha/beta ratio (renal cell carcinoma, CRPC, sarcoma, thyroid cancer, CRC, melanoma) | Procedure: Cryosurgery                                           |
|                       |                                                                       |       |    |                                        | • Radiation: Stereotactic Body Radiation Therapy                |

Abbreviations: CRC: colorectal cancer; CRPC: castration-resistant prostate cancer; N: Number of expected patients; NA: Not applicable; Number in clinicaltrials.gov; MKi: multikinase inhibitor.
| Locoregional treatment and MKi | MKi | Outcomes measures | Locations (countries) |
|-------------------------------|-----|-------------------|----------------------|
| Concurrent                    | Dabrafenib | Maximum tolerated dose of combination therapy of dabrafenib and trametinib administered concurrently with intensity-modulated radiation therapy (IMRT)  
|                               | Trametinib | Objective response rate  
|                               |           | Time to progression for local disease recurrence  
|                               |           | Overall survival Progression free survival | USA |
| Neoadjuvant                   | Lenvatinib | Overall R0/R1 resection rate  
|                               |           | Resection rate of R0  
|                               |           | Resection rate of R1  
|                               |           | Change in Surgical complexity and morbidity score (SCMS)  
|                               |           | Primary surgery response rate  
|                               |           | Number of Participants with Treatment Related Adverse Events as Assessed by CTCAE v 5.0  
|                               |           | Unresectable to resectable conversion rate | USA |
| Neoadjuvant                   | Selpercatinib | Objective response rate (ORR)  
|                               |           | Tumor response  
|                               |           | R0/R1 resection rates  
|                               |           | Progression free survival (PFS)  
|                               |           | Locoregional PFS  
|                               |           | Surgical morbidity/ complexity score  
|                               |           | Overall survival (OS)  
|                               |           | Incidence of adverse events  
|                               |           | Quality of life  
|                               |           | Patient-reported outcome | USA |
| Neoadjuvant                   | Dabrafenib | Overall response rate (ORR)  
|                               | Trametinib | Number of R0 resections after 3 months of neoadjuvant combination therapy with anti-BRAF and MEK inhibitors.  
|                               |           | Safety Profile (Number / Severity of Serious Adverse Events, SAEs)  
|                               |           | Percentage of patients who received a complete response 3 months after the first dose of treatment.  
|                               |           | Health-related quality of life  
|                               |           | Progression-Free Survival (PFS)  
|                               |           | Overall Survival (OS) | Russian Federation |
| Neoadjuvant                   | Dabrafenib | Complete gross surgical resection (R0 or R1 resection)  
|                               | Trametinib | Overall survival (OS)  
|                               | Pembrolizumab | Tumor response  
|                               |           | Progression free survival (PFS)  
|                               |           | Surgical morbidity/ complexity  
|                               |           | Number of patients with adverse events as a measure of safety of neoadjuvant dabrafenib, trametinib, and pembrolizumab  
|                               |           | Number of patients with adverse events as a measure of safety of postoperative pembrolizumab plus IMRT  
|                               |           | Locoregional control  
|                               |           | Health related quality of life  
|                               |           | Patient-reported symptoms | USA |
| Concurrent (allowed)           | Any targeted therapy | Pain response  
|                               |           | Daily morphine equivalent (MEDD)  
|                               |           | Duration of response  
|                               |           | Local control  
|                               |           | Rate and severity of adverse and serious related adverse events  
|                               |           | Technical success for cryoablation | USA |

Abbreviations: CRC: colorectal cancer; CRPC: castration-resistant prostate cancer; N: Number of expected patients; NA: Not applicable; Number in clinicaltrials.gov; MKi: multikinase inhibitor.
metastases. In addition, palliative embolization may reduce symptoms or be used prior to surgery. Its selective use for bone metastases may also be considered as palliative therapy because it reduces symptoms. However, embolization has also shown benefit in patients who have received concomitant treatment with radioiodine or radiotherapy. There are no robust data on the use of embolization with MKI treatment, although Rodia et al report a study in which a patient is coadministered lenvatinib treatment without complications. In this case, the authors propose a reduction in the dose of lenvatinib in the period around the procedure.

3.5 | Radiotherapy

A recent in vitro study shows how MKIs and radiation significantly inhibit thyroid cancer growth by uptake of tyrosine kinase inhibitor, although the paucity of clinical studies leads to heterogeneity in treatment and recommendations. For patients with locally advanced unresectable disease, when radioiodine fails to control local growth and spread of disease, external beam radiotherapy is suggested for palliation. Radiation therapy in thyroid cancer has a palliative function for pain control or to control the local growth of lesions that cannot be approached with other techniques. The specific anatomic area and tumor volume should be considered prior to therapy. Whole brain radiotherapy in patients with brain metastases usually has no survival benefit, while resulting in neurological impairment in some patients. However, recent improvements in radiotherapy support that other techniques with less toxicity such as radiosurgery or tomotherapy can be considered.

3.6 | Lenvatinib

From its introduction, the treatment indications for lenvatinib have increased, possibly leading to its combination with locoregional therapies eventually opening new ways of combined thyroid cancer treatment. Table 1 shows eight clinical trials that are currently recruiting patients and include locoregional strategies in the treatment of thyroid cancer. There are no results available yet.

Until there are sound published data to enable proper recommendations on the use of locoregional therapies during treatment with lenvatinib, assumptions can be made based on the previous recommendations specific for surgical procedures (Figure 1).

4 | DISCUSSION

When treating a patient with oligometastatic progression of RR-DTC, it is important to assess whether local techniques would provide benefit in terms of symptom control and can
positively influence a longer survival time. As there is currently no solid evidence on the use of locoregional strategies in conjunction with lenvatinib or other MKIs, these questions remain unresolved. For the time being, decision-making relies on the limited published real-world evidence and expert recommendations, while randomized clinical trials will provide stronger efficacy and safety data to better support clinical decisions in the future. This manuscript, in the absence of review articles in this field, aims to inform about the current state-of-the-art treatment to facilitate management of thyroid cancer with MKI therapy.

5 | CONCLUSION

The use of locoregional techniques during treatment with an MKI for thyroid cancer is feasible, although there is very little supportive scientific evidence to date. Overall, withdrawal of the MKI for a few days guarantees the absence of major complications, although it has also been proposed to reduce the dose during a specific window around the procedure. Currently, some clinical trials are under way that can provide more scientific evidence for the combination of locoregional techniques with an MKI.

AUTHORS’ CONTRIBUTIONS

Miguel Ángel Berciano Guerrero is the full author of the manuscript, as well as the tables and figures.

ETHICS STATEMENT

Not applicable.

ACKNOWLEDGMENTS

This manuscript was developed with editorial assistance by Mary Smith through an unrestricted grant supported by Eisai Farmacéutica SA, in accordance with Good Publication Practice (GPP3) guidelines (http://www.ismpp.org/gpp3).

FUNDING INFORMATION

The author received an honorarium payment from Eisai Farmacéutica SA in line with ICMJE guidelines.

CONFLICT OF INTEREST

Dr Miguel-Ángel Berciano-Guerrero has received research funding, honoraria, and non-financial or other support from BMS, MSD, Novartis, Pfizer, Pharmamar, Pierre-Fabre, Roche and Sanofi and non-financial or other support from Eisai Farmacéutica SA, BMS, MSD, Novartis, Pfizer, Pharmamar, Pierre-Fabre, Roche and Sanofi.

DATA AVAILABILITY STATEMENT

Not applicable.

ORCID

Miguel-Ángel Berciano-Guerrero © https://orcid.org/0000-0002-5437-5196

REFERENCES

1. Capdevila J, Galofré JC, Grande E, et al. Consensus on the management of advanced radioactive iodine-refractory differentiated thyroid cancer on behalf of the Spanish Society of Endocrinology Thyroid Cancer Working Group (GTSEEN) and Spanish Rare Cancer Working Group (GETHI). Clin Transl Oncol. 2017;19:279-287. doi:10.1007/s12094-016-1554-5
2. Kim M, Kim TH, Shin DY, Lim DJ, Kim EY, Kim WB, Chung JH, Shong YK, Kim BH, Kim WG; Korean Thyroid Cancer Study Group (KTCSG). Tertiary care experience of sorafenib in the treatment of progressive radioiodine-refractory differentiated thyroid carcinoma: a Korean multicenter study. Thyroid. 2018 Mar;28(3):340-348. doi: 10.1089/thy.2017.0356. Erratum in: Thyroid. 2018 May;28(5):686.
3. Gay S, Monti E, Trambaiolo Antonelli C, et al. Case report: lenvatinib in neoadjuvant setting in a patient affected by invasive poorly differentiated thyroid carcinoma. Future Oncol. 2019;15(24s):13-19. doi:10.2217/fon-2019-0099
4. Stewart KE, Strachan MWJ, Srinivasan D, MacNeill M, Wall L, Nixon JJ. Tyrosine kinase inhibitor therapy in locally advanced differentiated thyroid cancer: a case report. Eur Thyroid J. 2019;8(2):102-107. doi:10.1159/000494880
5. Haugen BR, Kane MA. Approach to the thyroid cancer patient with extracervical metastases. J Clin Endocrinol Metab. 2010;95(3):987-993. doi:10.1210/jc.2009-2305
6. Kitamura M, Hayashi T, Suzuki C, et al. Successful recovery from a subclavicular ulcer caused by lenvatinib for thyroid cancer: a case report. World J Surg Oncol. 2017;15(1):24. doi:10.1186/s12957-017-1096-5
7. Britt CJ, Russell JO. Tyrosine kinase inhibitor use and wound healing in tracheoesophageal punctures. Ear Nose Throat J. 2019;98(8):510-512. doi:10.1177/0145561319839805
8. Porcelli T, Sessa F, Caputo A, Catalini C, Salvatore D. Teriparatide replacement therapy for hypoparathyroidism during treatment with lenvatinib for advanced thyroid cancer: a case report. Front Endocrinol (Lausanne). 2018;7(9):244. doi:10.3389/fendo.2018.00244
9. Tori M, Shimo T. Long-term efficacy of lenvatinib for recurrent papillary thyroid carcinoma after multimodal treatment and management of complications: a case report. BMC Cancer. 2018;18(1):698. doi:10.1186/s12885-018-4612-2
10. Lenvatinib EMA SmPC (Lenvima®; Eisai Europe Ltd). Available at: www.ema.europa.eu/ema/ Accessed 8 April 2021.
11. Motzer R, Alekseev B, Rha SY, et al. Lenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma. N Engl J Med. 2021;384(14):1289-1300. doi:10.1056/NEJMoa2035716
12. Toda S, Iwasaki H, Murayama D, Nakayama H, Suganuma N, Masudo K. Invasive procedures in patients undergoing treatment with lenvatinib for thyroid cancer. Mol Clin Oncol. 2021;14(4):81. doi:10.3892/mco.2021.2243
13. Alshehri K, Alqurashi Y, Merdad M, Samargandy S, Daghistani R, Marzouki H. Neoadjuvant lenvatinib for inoperable thyroid cancer: A case report and literature review. Cancer Rep (Hoboken). 2022;5(2):e1466. doi:10.1002/cnr2.1466

14. Lewis BD, Hay ID, Charboneau JW, McIver B, Reading CC, Goellner JR. Percutaneous ethanol injection for treatment of cervical lymph node metastases in patients with papillary thyroid carcinoma. AJR Am J Roentgenol. 2002;178(3):699-704. doi:10.2214/ajr.178.3.1780699

15. Dupuy DE, Monchik JM, Decrea C, Pisharodi L. Radiofrequency ablation of regional recurrence from well-differentiated thyroid malignancy. Surgery. 2001;130(6):971-977. doi:10.1067/mss.2001.118708

16. Lee SJ, Jung SL, Kim BS, et al. Radiofrequency ablation to treat loco-regional recurrence of well-differentiated thyroid carcinoma. Korean J Radiol. 2014;15(6):817-826. doi:10.3348/kjr.2014.15.6.817

17. Porcelli T, Sessa F, Luongo C, Salvatore D. Local ablative therapy of oligoprogressive TKI-treated thyroid cancer. J Endocrinol Invest. 2019;42(8):871-879. doi:10.1007/s40618-019-1001-x

18. Eustatia-Rutten CF, Romijn JA, Gujit MJ, et al. Outcome of palliative embolization of bone metastases in differentiated thyroid carcinoma. J Clin Endocrinol Metab. 2003;88(7):3184-3189. doi:10.1210/jc.2003-030231

19. Gagey O, Court C, Zlad N, Schlumberger M. Localisations pelviennes et rachidiennes de métastases géantes des carcinomes thyroïdiens: à propos de 8 cas [Pelvic and spinal giant metastases from thyroid carcinomas: report of 8 cases]. Rev Chir Orthop Reparatrice Appar Mot. 2001;87(6):579-584.

20. Van Tol KM, Hew JM, Jager PL, Vermeer A, Dullaart RP, Links TP. Embolization in combination with radioidine therapy for bone metastases from differentiated thyroid carcinoma. Clin Endocrinol (Oxf). 2000;52(5):653-659. doi:10.1046/j.1365-2265.2000.00998.x

21. Rodia R, Marini S, Pani F, Boi F, Mariotti S. Embolization of iliac metastasis during lenvatinib treatment in patient with advanced Hürthle cell thyroid carcinoma. Future Oncol. 2019;15(24s):35-40. doi:10.2217/fon-2019-0184

22. Suzuki K, Iwai H, Utsunomiya K, et al. Combination therapy with lenvatinib and radiation significantly inhibits thyroid cancer growth by uptake of tyrosine kinase inhibitor. Exp Cell Res. 2021;398(1):112390. doi:10.1016/j.yexcr.2020.112390

23. Ishigaki T, Urutu T, Sugino K, et al. Stereotactic radiotherapy using the CyberKnife is effective for local control of bone metastases from differentiated thyroid cancer. J Radiat Res. 2019;60(6):831-836. doi:10.1093/jrr/rrz056

24. Mathis NJ, Wijetunga NA, Imber BS, Pike LRG, Yang JT. Recent advances and applications of radiation therapy for brain metastases. Curr Oncol Rep. 2022;24(3):335-342. doi:10.1007/s11912-022-01209-z

25. Brown PD, Ballman KV, Cerhan JH, et al. Postoperative stereotactic radiosurgery compared with whole brain radiotherapy for resected metastatic brain disease (NCCTG N107C/CEC-3): a multicentre, randomised, controlled, phase 3 trial. Lancet Oncol. 2017;18(8):1049-1060. doi:10.1016/S1470-2045(17)30441-2

How to cite this article: Berciano-Guerrero M-Á. Use of multikinase inhibitors/lenvatinib concomitant with locoregional therapies for the treatment of radioiodine-refractory differentiated thyroid cancer. Cancer Med. 2022;11(Suppl. 1):40-46. doi: 10.1002/cam4.5108